Spironolactone for Hormonal Acne: Uses, Timeline, and Safety

Spironolactone is one of the most effective treatments for hormonal acne in women, working by blocking the androgen hormones that drive oil production in the skin. Originally developed in the 1960s as a blood-pressure and fluid-retention drug, it found a second life in dermatology because of its anti-androgen properties. It remains off-label for acne, meaning no regulatory agency has formally approved it for that purpose, but decades of clinical use and a growing body of trial data have made it a mainstream prescription for adult women whose breakouts resist conventional treatments.

How Spironolactone Targets Acne

Acne in adult women is frequently driven by androgens, the group of hormones that includes testosterone and its more potent derivative, DHT. These hormones stimulate the sebaceous glands to produce excess oil, which clogs pores and feeds the bacteria involved in inflammation. Spironolactone works at the hormonal level rather than at the skin surface: it blocks androgen receptors so that testosterone and DHT have less effect on the oil glands. It also reduces androgen production to a degree. The result is less oil, fewer clogged pores, and over time, less inflammation.¹

This hormonal mechanism is why spironolactone is prescribed almost exclusively to women. In men, blocking androgens can cause breast tissue growth, reduced libido, and other feminizing effects that make the drug impractical for treating acne. Women considering spironolactone also need reliable contraception, because the drug can interfere with the development of a male fetus. These constraints shape who the drug is appropriate for, but within that population it fills a gap that topical products and antibiotics often cannot.

How Well It Works

The efficacy data for spironolactone have strengthened considerably in recent years. A meta-analysis pooling randomized, placebo-controlled trials found that women taking spironolactone were roughly six times more likely to achieve clear or near-clear skin on standardized acne scales compared to those on placebo.² That is a large effect size by dermatology standards, where many topical treatments struggle to outperform placebo by much.

Real-world data paints a similar picture. A retrospective review of nearly 400 patients treated at Mayo Clinic found that about two-thirds achieved a complete response and roughly 85% had at least a greater-than-50% improvement. The drug worked across mild, moderate, and severe cases, including the deeper, painful nodulocystic type that is notoriously stubborn.³ That breadth of efficacy is one reason dermatologists reach for spironolactone when first-line treatments plateau.

It is worth noting that the randomized trial evidence was historically thin. An earlier systematic review found that most older trials had small sample sizes or flawed designs, and that only one crossover trial had clearly demonstrated statistical superiority over placebo at a 200 mg daily dose.⁴ The more recent placebo-controlled trials and the SAFA trial in the UK have filled much of that gap, but the evidence base is still younger than you might expect for a drug prescribed this widely.

How Long Before You See Results

Patience matters here. Spironolactone does not work like an antibiotic or a benzoyl peroxide wash that might visibly reduce a breakout within days. Because it targets the hormonal signal upstream of oil production, the downstream effects take time to materialize. The Mayo Clinic review found a median time to initial response of three months and a median time to maximum response of five months.⁵

The UK’s SAFA trial, the largest randomized controlled trial of spironolactone for acne to date, added helpful detail to this timeline. At 12 weeks, the difference between spironolactone and placebo was modest, and patient-reported improvement rates were close. By 24 weeks, the gap widened substantially: about 82% of women on spironolactone reported overall acne improvement compared to roughly 63% on placebo.⁶ The practical takeaway is that if you start spironolactone, you should plan to give it at least three to six months before judging whether it is working. Dermatologists often pair it with a topical retinoid or benzoyl peroxide during that ramp-up period to manage breakouts while the hormonal effect builds.

Side Effects and Tolerability

Spironolactone is generally well tolerated at the doses used for acne, which typically range from 50 to 200 mg daily. Most dermatologists start at 50 or 100 mg and adjust based on response. The side effects that do occur tend to reflect the drug’s hormonal and diuretic properties:

Menstrual changes: Irregular periods, spotting, or heavier flow are the most commonly reported side effects. In a retrospective study of 110 women, menstrual side effects were the most frequent complaint.⁷ Taking a combined oral contraceptive pill alongside spironolactone often mitigates this issue and also provides the pregnancy prevention that the drug requires.
Breast tenderness: Because blocking androgens tips the relative balance toward estrogen, some women notice breast soreness or mild swelling.
Dizziness or lightheadedness: Spironolactone can lower blood pressure slightly, which is occasionally noticeable when standing up quickly. Staying hydrated helps.
Increased urination: As a diuretic, it can send you to the bathroom more frequently, especially early on. Many people find this effect diminishes after the first few weeks.

Serious side effects are rare at dermatologic doses. Most women tolerate the drug well enough to stay on it long-term, and the FASCE trial comparing spironolactone to doxycycline described spironolactone as “very well tolerated.”⁸

Do You Really Need Potassium Checks?

Because spironolactone is a potassium-sparing diuretic in its original cardiac use, many prescribers reflexively order periodic blood tests to check potassium levels. In heart-failure patients, who are older, often on multiple medications, and may have kidney impairment, this monitoring makes sense. But the population taking it for acne looks nothing like that: they are overwhelmingly young, healthy women on low to moderate doses.

A study published in JAMA Dermatology examined this question directly and found that the rate of high potassium in healthy young women on spironolactone for acne was no different from the background rate in that population. The authors concluded that routine potassium monitoring is unnecessary for healthy women taking the drug for acne.⁹ Some dermatologists still check a baseline level and perhaps one follow-up, but the evidence does not support the kind of frequent lab draws that were once standard practice. If you have kidney disease, are on other medications that raise potassium, or are over 45, the calculation changes and regular monitoring remains appropriate.

Spironolactone vs. Antibiotics for Acne

For years, oral antibiotics like doxycycline and minocycline have been the default systemic treatment for moderate acne. They work, but they come with a problem: the longer you take them, the more you contribute to antibiotic resistance, both in the bacteria on your skin and in your body more broadly. Dermatology guidelines increasingly push to limit antibiotic courses to three or four months, which creates a gap for patients who need longer-term management.

The FASCE study, a multicenter randomized trial, compared spironolactone head-to-head against doxycycline in adult women with moderate acne. Spironolactone performed better at four months and was nearly three times as likely to achieve treatment success at six months. Lesion counts, standardized acne scores, and quality-of-life measures all favored spironolactone, and it was better tolerated.¹⁰ The advantage of spironolactone is that because it is not an antibiotic, it can be continued indefinitely without resistance concerns. This makes it a strong option for women whose acne tends to relapse when treatment is stopped, which is common in hormonally driven breakouts.

The Cancer Question

A persistent worry about spironolactone, especially for long-term use, is whether its anti-androgen effects could increase the risk of hormone-sensitive cancers like breast or ovarian cancer. This concern has been around for decades and occasionally gets amplified on social media. The evidence, taken together, is reassuring.

A large retrospective cohort study of women over 55 found no increased incidence of breast cancer with spironolactone use, with a hazard ratio of essentially 1.0.¹¹ A systematic review and meta-analysis in JAMA Dermatology pooled data across multiple studies and found no statistically significant association between spironolactone and breast, ovarian, bladder, kidney, gastric, or esophageal cancers.¹²

A separate population-level study initially observed a 10 to 30% increase in breast and gynecologic cancers in spironolactone users, but the same increases appeared in users of furosemide, a diuretic with no hormonal activity at all. When the researchers looked more closely, the elevated rates were concentrated in the first year of drug exposure and were driven by cancers diagnosed very shortly after starting the medication. The authors concluded this was reverse causality: symptoms from an undiagnosed cancer likely prompted the prescriptions, rather than the drugs causing the cancer.¹³ For women in their 20s and 30s taking the drug for acne, the existing evidence provides no reason for cancer-related alarm.

What Happens When You Stop

Because spironolactone treats the hormonal driver of acne rather than eliminating it permanently, there is a reasonable expectation that acne could return after stopping the drug. How quickly and how consistently that happens is something many patients and their doctors wonder about.

A study tracking patients with hyperandrogenic skin conditions (including acne) after spironolactone withdrawal found that about two-thirds maintained prolonged improvement for an average of nearly three years after stopping. The remaining third relapsed, on average about a year and a half after discontinuation. Women with classic polycystic ovary syndrome tended to hold their improvement longer than those with an ovulatory subtype of PCOS.¹⁴ This suggests the drug may have some lingering benefit after discontinuation for some women, though the mechanism behind that lasting effect is not well understood. Many dermatologists recommend tapering gradually rather than stopping abruptly, and having a topical maintenance regimen in place before discontinuing.

PCOS-Related Acne

Women with polycystic ovary syndrome often have elevated androgen levels, which makes them especially prone to hormonal acne along the jawline, chin, and lower face. Spironolactone is a natural fit for this population because it directly addresses the androgen excess at the root of both the skin symptoms and other PCOS-related issues like excess facial or body hair.

A study specifically examining spironolactone in women with PCOS found that it reduced scores on a clinical scale for excess hair growth in both lean and overweight participants, and that acne improved in most of those who had it at baseline.¹⁵ For women dealing with both acne and hirsutism, spironolactone addresses two problems with a single prescription, which is a significant practical advantage over treatments that only target one symptom.

Quality of Life Beyond Lesion Counts

Clinical trials typically measure acne outcomes by counting pimples or using standardized severity scales, but those metrics do not always capture what matters most to the person looking in the mirror. Acne’s psychological burden is well documented, and for many adults, persistent breakouts affect confidence, social comfort, and daily functioning in ways that a lesion count does not reflect.

A randomized trial comparing oral spironolactone to topical azelaic acid found that both treatments led to significant improvements across all domains of an acne-specific quality-of-life questionnaire, with no meaningful difference between the two groups.¹⁶ The FASCE trial also found quality-of-life scores favoring spironolactone over doxycycline at both four and six months.¹⁷ These findings matter because they confirm that the clinical improvements are translating into how patients actually feel about their skin.

Topical Spironolactone and Clascoterone

The idea of putting spironolactone directly on the skin is appealing because it could potentially deliver anti-androgen effects to the oil glands without the systemic side effects. Small studies have explored topical spironolactone, typically as a 5% cream or gel. A randomized controlled trial found that 5% spironolactone gel reduced total lesion counts compared to placebo, though the effect on an overall acne severity index did not reach statistical significance.¹⁸ A pilot study also showed some promise but acknowledged limitations including small sample size and uncertainty about whether topical application could lead to meaningful systemic absorption.¹⁹

A related development is clascoterone, a topical anti-androgen that received FDA approval for acne in 2020. Clascoterone works similarly to spironolactone in blocking androgen receptors at the oil gland, but it was designed specifically for topical use and lacks the activity at mineralocorticoid receptors that gives spironolactone its blood-pressure and potassium effects. A review noted that despite their structural similarity, the two compounds differ enough in mechanism that they are not considered interchangeable, and there is not yet enough pharmacokinetic data to know whether topical spironolactone is safe for people who cannot take the oral form.²⁰ Clascoterone’s advantage is that it can be prescribed to both men and women, since its effects stay local to the skin. Its disadvantage, for now, is cost and limited long-term data compared to a drug that has been in use for over 60 years.

Why It Remains Off-Label

Given the evidence, a reasonable question is why spironolactone still has not been officially approved for acne by any major regulatory body. The answer has more to do with economics and history than safety concerns. Spironolactone has been generic since long before anyone thought to study it rigorously for acne, and no pharmaceutical company has the financial incentive to fund the large-scale regulatory trials that an approval would require. The drug costs very little, patent protection expired decades ago, and the return on investment for a formal acne indication would not justify the expense.

Dermatologists have worked around this by prescribing it off-label, which is perfectly legal and common across many areas of medicine. Professional guidelines from organizations like the American Academy of Dermatology include spironolactone in their acne treatment algorithms for adult women. The evidence continues to accumulate through investigator-initiated trials and publicly funded research like the SAFA trial in the UK, gradually building the kind of evidence base that would normally precede regulatory approval but in this case follows widespread clinical adoption.